TSG101 has been identi®ed as a candidate tumor suppressor gene and abnormal transcripts have been identi®ed in a substantial fraction of breast cancers. To determine whether TSG101 expression is commonly altered in other tumors, a series of 15 primary and metastatic prostate cancers were analysed by reverse transcriptase-PCR ampli®cation. Abnormal transcripts with extensive deletions in the coding region were found in nine of these tumors, while only the normal transcript was found in control and benign prostatic hypertrophy tissues. More than one abnormal transcript was found in four of these nine cases and distinct abnormal TSG101 transcripts were found in separate biopsies taken from one tumor. Importantly, the normal TSG101 transcript was undetectable in two metastatic prostate cancers, indicating the absence of TSG101 protein. Sequence analysis demonstrated that there were at least six distinct deletions, with four of these deletions found in more than one tumor sample. The most commonly identi®ed deletion, from bp 153 to 1055, was identical to a deletion reported previously in breast cancer. These results demonstrate that TSG101 transcripts are frequently abnormal in prostate cancer and suggest that loss of TSG101 protein contributes to disease development or progression.
Introduction
Prostate cancer (PCa) is currently the most common malignancy in males and causes more than 40 000 deaths in the United States annually (Parker et al., 1996) . Androgens and a functional androgen receptor are required for the development of PCa. However, despite considerable eort, the identity of additional genes which contribute to the development of PCa remains unclear. Tumor susceptibility gene 101 (TSG101) was identi®ed in a screen using homozygous disruption in mouse ®broblasts to identify candidate tumor suppressors (Li and Cohen, 1996) . The TSG101 gene encodes a 43 kDa protein with a proline-rich domain and a leucine zipper containing coiled-coil domain, suggesting that it functions as a transcription factor (Li and Cohen, 1996) . Functional inactivation of TSG101 by antisense RNA in mouse ®broblasts leads to transformation and the ability to form metastatic tumors in nude mice, although overexpression of this gene also results in cellular transformation (Li and Cohen, 1996) .
The human TSG101 gene is 94% homologous to the murine gene at the protein level and has been localized to chromosome 11p15.1-15.2, a region showing loss of heterozygosity (LOH) in a variety of human malignancies (Li et al., 1997) . A recent analysis of TSG101 transcripts in primary human breast carcinomas revealed a series of deletions, although the normal transcript was also detected in all cases (Li et al., 1997) . The many biological similarities between breast cancer and PCa prompted us to examine TSG101 expression in PCa. In this study, TSG101 transcripts from 15 cases of primary and metastatic PCa were analysed by RT ± PCR. Overall, deletions were detected in nine cases, including both primary and metastatic prostate cancers. Two or more deletions were found in multiple samples and distinct deletions were observed in two separate biopsies from the same patient. In two biopsies there was no evidence of the normal TSG101 transcript. Sequence analysis demonstrated that there were at least six distinct deletions, with four of these deletions found in more than one tumor sample. The deletions removed large portions of the coding region. These results indicate that loss of TSG101 protein is common in PCa and that this could represent a signi®cant step in tumor progression.
Results
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transcripts from a series of prostate cancers (Table 1) and prostate epithelial and stromal cells from benign prostatic hypertrophy (BPH) were analysed by RT ± PCR using primers that bracketed the TSG101 protein coding region (Figure 1a ). In the three tumor samples derived from radical prostatectomies (PCa1-3), matched prostate tissue which was microscopically free of tumor was also examined. In these later tumor free prostate samples and in the BPH samples, the predicted full length 1145 bp TSG101 transcript was the only signi®cant product observed (Figure 2a ). The full length transcript was also the only product in the PCa1 and two other tumors, but a minor second band of about 170 bp was observed in the PCa3 tumor sample. Sequence analysis con®rmed that this second band was a TSG101 transcript with a large deletion (see below).
Tumor tissue derived from transurethral prostatectomies (channel TURPs) in patients with more advanced disease (PCa4-6), yielded readily detectable abnormal bands (Figure 2a ). These were also con®rmed by sequencing to be derived from TSG101 and contained large deletions. In PCa5, two biopsies where obtained and yielded distinct abnormal transcripts (PCa5, T1 and T2). Analyses of distant metastases in nine additional cases (PCa8-16) yielded abnormal TSG101 transcripts in ®ve tumors (Figure 2b) . Signi®cantly, the full length TSG101 transcript was undetectable in two of these latter cases (PCa8 and 10) and was only a minor product in two other cases (PCa11 and 14). Overall, tumors from eight of twelve patients with advanced diseases had products consistent with abnormal transcripts.
To con®rm the identity of these RT ± PCR products as TSG101 transcripts and to map the deletions, multiple full length and abnormally sized PCR fragments were isolated and sequenced. No point mutations or deletions were observed in the full length transcripts from the three matched normal prostate tissues (PCa1-3, data not shown). Sequence analyses of 15 abnormal bands revealed six dierent deletions, all of which removed most of the TSG101 coding region. As indicated in Table 1 , four of these six deletions also changed the reading frame. The sequences around these deletions are shown in Figure  3 and the deletions are outlined in Figure 1 . The abnormal transcript designated form four included a 42 bp insertion between nt 132 and 133 (Figures 1 and  3b) .
The transcript containing a deletion between bp 153 to 1055 (form 1) was most commonly detected, occurring in six of the PCa tumors (Table 1) . This deletion was identical to one described previously as a 153 to 1053 deletion in human breast cancer (Li et al., 1997) . Forms 2, 5, and 6 were also identi®ed in more than one tumor. Form 4, which contained a 42 bp insertion between nt 132 and 133 and a deletion from nt 153 to 1055, was only found in one sample (PCa5T1). However, form 4 was similar to an abnormal transcript described in breast cancer, which was reported as a 63 bp insertion between nt 133 and 1054 (sequence data in that report indicates that the 63 bp insertion includes the region between nt 133 and 153, as in form 4) (Li et al., 1997). (1) Prostate ( PCa3 was derived from a radical prostatectomy and PCa4-6 were derived from transurethral prostatectomies (channel TURPs) in patients with advanced androgen independent prostate cancer A 1145 bp band representing the normal transcript is also indicated. No speci®c DNA band was detected in a reaction without template DNA used as a negative control (NC). Standard 1 Kb ladder (GIBCO) was used as a molecular weigh marker (MW). (b) RT ± PCR products from metastatic tumors. As described above, the tumor samples were analysed by RT ± PCR and electrophoresis
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Due to the small amounts of tumor tissue available, these studies of TSG101 transcripts have necessarily been done by RT ± PCR and con®rmation through Northern blot or nuclease protection experiments has not been possible. The ®nding of only full length TSG101 transcripts in biopsies without tumor suggests that the deletions found in the tumor samples were not artifacts of the PCR ampli®cation. The complete absence of full length TSG101 transcripts in two samples (PCa8 and 10) was also inconsistent with an ampli®cation artifact. The possible contamination of the tumor samples with factors which could produce a bias towards truncated PCR products was further addressed by an analysis of additional transcripts in the same samples which contained abnormal TSG101 transcripts. RT ± PCR analyses were carried out to examine transcripts of FHIT Sozzi et al., 1996) and b2-microglobulin (Gussow et al., 1987) . In contrast to the TSG101 results, only full length transcripts were detected (Figure 4a and b) .
Discussion
This report indicates that abnormal TSG101 transcripts are common in prostate cancer. These abnormalities all involved deletion of most of the coding region, indicating that any protein derived from these transcripts would be nonfunctional. The extensive deletions of the coding region also make very unlikely the production of proteins which would have dominant negative eects. These observations indicate that TSG101 may function as a tumor suppressor in prostate cancer. Further crucial evidence for this hypothesis would be the demonstration that both TSG101 genes were nonfunctional in tumor cells. Unfortunately, both in this study and in the previous study in breast cancer (Li et al., 1997) , normal full length TSG101 transcripts were also ampli®ed from most tumor samples. Although these full length transcripts may have been derived from the substantial numbers of normal cells contained in most fresh tumor samples, an origin from the tumor cells could not be excluded. Therefore, in this report the identi®cation of two prostate cancer samples with no detectable full length TSG101 transcripts, and presumably no normal TSG101 protein, provides important support for the hypothesis that TSG101 can function as a tumor suppressor.
Although LOH at 11p15, the location of the human TSG101 gene, has been observed in many tumors, it is not yet clear whether deletions in the TSG101 gene account for the precise deletions seen in TSG101 transcripts from multiple tumors. Sequence analysis of the abnormal TSG101 transcripts in this report showed identical deletions in multiple tumors. The most common abnormal transcript was form 1, a deletion from bp 153 to 1055, which was identi®ed in six patients (six tumor samples). This identical deletion was also reported previously in tumor samples from breast cancers (Li et al., 1997) . It is noteworthy that consensus sequences for RNA splicing are observed at Figure 4 Detection of FHIT and b2-microglobulin transcripts by RT ± PCR. Thirteen cDNA samples from tumor (T) and a matched normal (N) tissue sample of prostate cancer patients as described above were ampli®ed to detect FHIT and b2-microglobulin transcripts. PCR products were analysed on 1.6% agarose gels. The 615 bp and 658 bp bands representing the normal transcripts of FHIT (a) and b2-microglobulin (b), respectively, are indicated. The jw 174/HaeIII (New England Biolab) was used as a molecular weight marker (MW). A negative control was indicated as NC Tumor susceptability gene in prostate cancer Z Sun et al the 5' and 3' ends of deleted sequences in the abnormal forms 1, 3 and 5 (see Figure 5 ) (Kramer, 1996; le et al., 1986) . Therefore, alternative splicing due to diverse and potentially subtle alterations in the TSG101 gene (deletions, insertions and/or point mutations) may account for the precise deletions seen in multiple prostate and breast cancers. Direct structural studies of the TSG101 gene will require larger amounts of tissue containing a high proportion of tumor cells or appropriate cell lines. If TSG101 does function as a tumor suppressor, it is not clear whether it is lost as an early or late event in carcinogenesis. The frequency of abnormal transcripts in more advanced prostate cancers from channel TURPs (PCa4-6) and from metastatic sites (PCa8-16), appeared to be greater than in the radical prostatectomy samples (PCa1-3) . However, PCa samples derived from radical prostatectomies contain a large fraction of normal epithelial and stromal cells, making it dicult to quantitatively assess abnormal TSG101 transcripts derived from the tumor. Several of the advanced prostate cancers expressed more than one abnormal transcripts. Analyses of additional minor bands in some of these advanced tumors suggest further heterogeneity (data not shown). If each of these abnormal transcripts represents a distinct genetic alteration, then these observations would suggest that loss of TSG101 is a later event. A previous report also suggested that loss of TSG101 may not be an early event (Li and Cohen, 1996) . Eorts to analyse TSG101 expression directly in early and late stage tumors by immunohistochemistry and in situ hybridization are underway.
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The predicted TSG101 protein structure is suggestive of a transcription factor, with a leucine zipper containing coiled-coil domain and a proline rich region consistent with a transactivation domain (Mitchell and Tjian, 1989) . A previous report showing that TSG101 may interact with stathmin provides a clue as to the mechanism through which this protein may function as a tumor suppressor (Johnson et al., 1995) . Stathmin, also termed Oncoprotein 18, phosphoprotein 18, and p19, is a highly conserved 19 kDa cytoplasmic protein which is phosphorylated in response to a wide variety of signals (Beretta et al., 1993; Chneiweiss et al., 1989; Duraj et al., 1995; Leighton et al., 1993; Nakamura et al., 1995; Sobel, 1991) . These observations suggest that TSG101 may function as a transcription factor downstream of stathmin to suppress cell growth and that stathmin may stimulate cell growth in part through binding and sequestering of TSG101. Finally, since TSG101 expression appears to be ubiquitous, it may contribute to the development of progression of tumors in addition to breast and prostate cancers.
Materials and methods
Patient tissues
A total of 16 tumor samples from 15 prostate cancer patients were analysed in this study. Tumor and matched normal tissues were obtained from radical prostatectomies in three cases. Tumor was also obtained from channel transurethral prostatectomies (channel TURPs) and biopsies from metastatic sites in patients with more advanced Figure 5 Sequences of human TSG101 cDNA and deletions. Full length cDNA sequence of TSG101 gene is represented and the predicted translation start site and stop codon are underlined. The ®rst nucleotides of each exon are marked with an arrowhead, based on the previously published sequence (Li et al., 1997) . The detailed sequences of the six abnormal transcripts identi®ed here in human prostate cancer are shown. The nucleotides immediately 5' and 3' of the deletions were bolded and underlined as well as marked by arrowheads above and below, respectively. The sequence of the 42 bp insertion in abnormal form 4 marked by * is shown in Figure 3b . The potential sequences for RNA splicing are boxed at the 5' and 3' ends of deleted sequences in the abnormal forms 1, 3 and 5 androgen independent PCa. Among 16 tumor samples, seven were from prostate and nine from metastatic sites (seven from bone marrow, one from a skin nodule, and one from a malignant pleural eusion). In patient 5 (PCa5), two tumor samples from the prostate were isolated and used in this study. The presence of tumor in all samples was con®rmed microscopically, although the ratio of tumour to normal tissue varied. Stromal and epithelial cells fractions were prepared by collagenase digestion followed by dierential centrifugation.
RNA extraction and RT ± PCR
Both tumor and normal specimens were frozen immediately after surgical resection or biopsy and stored in liquid nitrogen. Total RNA was extracted from frozen tissues using RNAzol B (TEL-TEST Inc, Friendswood, TX). cDNA was synthesized from 3mg of total RNA in a 10ml volume with 10 mM DTT, 500 mM dNTPs, 50 ng/oligo(dT) (Pharmacia), 20 unit of RNasin (Promega) and 25 units of AMV reverse transcriptase (Promega). The total RNA samples were ®rst heated for 5 min at 728C, before enzyme addition, and were then incubated at 428C for 90 min. The reaction was stopped by inactivating the enzyme at 958C for 5 min. The reaction was diluted to 100ml, and 1ml aliquots were used for subsequent PCR ampli®cations.
Primary PCR ampli®cations were performed in a 20ml volume containing 1ml of cDNA, 0.8 mM of P1 primer (5'-CGGGTGTCGGAGAGCCAGCTCAAGAAA-3') and P2 primer (5'-CCTCCAGCTGGTAGCAGAGAAGTCGT-3'), 50 mM dNTP and 0.5 unit of Taq polymerase (Promega) (see Figure 1) . The PCR reaction consisted of an initial denaturation at 958C for 2 min and 25 cycles of 30 s at 958C, 40 s at 628C and 1 min at 728C, and ®nal extension of 7 min at 728C using a Perkin-Elmer PCR themocycler. The ampli®ed product was diluted 20-fold in TE buer, and 1ml of the diluted reaction product was subjected to a second round of PCR ampli®cation using two nested primers P3 (5'-AGCCAGCTCAAGAAAATGGTGTCCAAG-3') and P4 (5'-TCACTGAGACCGGCAGTCTTTCTTGCTT-3').
The primers were identical to those described previously (Li et al., 1997) . The PCR reaction was also carried out in a 20 ml volume for 30 cycles of 958C for 45 s, 648C for 40 s and 728C for 1 min. The PCR products were analysed on 1.6% agarose gels and stained with ethidium bromide.
Ampli®cation of FHIT gene was performed exactly as described previously Sozzi et al., 1996) . 1ml of cDNA was used in primary ampli®cations with 5U2 and 3D2 primers. Subsequently, 1ml of 20-fold diluted primary PCR product was ampli®ed using nested 5U1 and 3D1 primers. Human b2 microglobulin transcripts were ampli®ed for 37 cycles of 30 s at 958C, 40 s at 568C, 30 s at 728C and ®nal extension of 7 min at 728C. The sequences of the primers were 5'-ATCCAGCGTACTCCAAAGATTCAG-3' and 5'-AAATTGAAAGTTAACTTATGCACGC-3' (Gussow et al., 1987) .
cDNA subcloning and sequencing
To further analyze potential abnormal TSG101 transcripts, ampli®ed PCR samples were resolved on a series of 1.6% low melting agarose gels. Each DNA band which could be clearly visualized as distinct from wild-type was excised from the gels. The agarose was digested using b-agarase (New England, Biolabs) and DNA was precipitated with 100% ethanol. The DNA was dissolved in 10 ± 15ml TE buer and 20 ± 40 ng of DNA was used for ligation with the pCR II T-vector (Invitrogen). The ligation mixtures were transformed into DH5a competent cells and at least two plasmids derived from each DNA band in each patient sample were sequenced. In all cases, the insert size of the plasmids matched the products isolated from the gels. Sequencing was carried out in both directions by the dideoxynucleotide termination reaction using Sequenase (US Biologicals).
